Testicular germ cell tumor (TGCT) is a highly curable malignancy treated with surgery, radiotherapy, and chemotherapy. While survival rates are excellent, many survivors experience significant long-term toxicities that affect quality of life. These include increased risks of second malignancies, cardiovascular disease, and cisplatin-induced peripheral neuropathy, as well as psychosocial issues such as anxiety, fear of recurrence, and sexual dysfunction. The severity of late adverse effects often
Conditions
Interventions
Germ cell tumor patients treated at Ramathibodi Hospital between 2010 and 2019. All patients achieved CR following first-line platinum-based chemotherapy.
Supportive Care
Surveillance group
Sponsors
None listed
Eligibility
Sex/Gender
Male
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Patients will be included if they meet all the following criteria: 1. Aged over 18 years at the time of diagnosis. 2. Histologically confirmed diagnosis of a testicular germ cell tumor (TGCT). 3. Received chemotherapy treatment and achieved a complete response (CR) with no residual disease. 4. Treated and registered in the Ramathibodi Cancer Registry database at Ramathibodi Hospital between 2009 and 2019.
Exclusion criteria
Exclusion criteria: Inability to be contacted or followed up for data collection. 1. Ongoing treatment or presence of residual disease at the time of evaluation. 2. Death prior to study evaluation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Late adverse events July 2024- Dec 2024 observational design | — |
Secondary
| Measure | Time frame |
|---|---|
| Sexual quality of life assessment July 2024- Dec 2024 Erectile Function-5 (IIEF-5) questionnaire score | — |
Countries
Thailand
Contacts
Public ContactPhichai Chansriwong
Ramathibodi Hospital
Outcome results
None listed